Minerva Neurosciences | NERV - Trade Creditors


Minerva Neurosciences reported $640K in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
Adma Biologics USD 35.66M 3.94M Sep/2026
ALKERMES USD 107.69M 35.17M Sep/2026
Alterity Therapeutics Limited AUD 1.07M 203.72K Dec/2025
AstraZeneca USD 23.57B 679M Sep/2026
BioCryst Pharmaceuticals USD 14.58M 3.12M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Cipla INR 32.66B 361.1M Sep/2026
Clal Biotechnology ILS 21.05M 1.62M Dec/2021
Compugen USD 2.15M 371K Jun/2026
CSL USD 3.17B 290M Dec/2025
Eli Lilly USD 5.79B 319M Sep/2026
GlaxoSmithKline GBP 15.63B 1.29B Sep/2026
Grifols EUR 987.75M 47.87M Dec/2025
Halozyme Therapeutics USD 33.55M 9.94M Sep/2026
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
J&J USD 9.32B 94M Sep/2026
Merck USD 5.03B 1.2B Sep/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Novartis USD 4.24B 15M Sep/2026
Novavax USD 24.94M 2.01M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sanofi EUR 24.55B 957M Sep/2026
Takeda JPY 486.2B 39.41B Sep/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024